摘要为了改善体外受精-胚胎移植( in vitro fertilization-embryo transfer，IVF-ET)治疗的结局，重组人生长激素(recombinant human growth hormone，rhGH)在辅助生殖技术中被广泛应用，特别是对于卵巢储备功能减退(diminished ovarian reserve，DOR)、卵巢低反应(poor ovarian response，POR)、多囊卵巢综合征(polycystic ovarian syndrome，PCOS)等卵巢功能异常患者，以及胚胎反复种植失败(repeated implantation failed，RIF)、薄型子宫内膜、宫腔粘连(intrauterine adhesion，IUA)等异常子宫内膜患者有较明显的改善作用，但目前对于rhGH的适用人群及使用方法尚无统一标准。本文就rhGH在以上人群中的具体应用及作用机制作一综述。

abstractsIn order to improve the outcome of in vitro fertilization-embryo transfer (IVF-ET) treatment, recombinant human growth hormone (rhGH) has been widely used in assisted reproductive technology (ART)， and has obvious improvement in patients with ovarian dysfunc-tion, such as diminished ovarian reserve (DOR), poor ovarian response (POR), polycystic ovary syndrome (PCOS), and abnormal endometrium patients such as repeated implantation failed (RIF), thin endometrium and intrauterine adhesions (IUA). But there is no unified standard about the target patients and application protocol of rhGH. This paper summarizes the mechanism and usage of rhGH in the above patients.